AstraZeneca PLC (STO: AZN)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 2.77T |
| Revenue (ttm) | 520.76B |
| Net Income (ttm) | 68.26B |
| Shares Out | n/a |
| EPS (ttm) | 43.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Aug 8, 2024 |
| Volume | 154,526 |
| Open | 1,782.50 |
| Previous Close | 1,787.50 |
| Day's Range | 1,781.00 - 1,796.00 |
| 52-Week Range | 1,261.00 - 1,796.00 |
| Beta | 0.15 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2024 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus... [Read more]
Financial Performance
In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.
Financial numbers in USD Financial StatementsNews
Competitor Analysis: Evaluating Johnson & Johnson And Competitors In Pharmaceuticals Industry
In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry com...
AstraZeneca share price has gone vertical; brace for a pullback
AstraZeneca (LON: AZN) share price is firing on all cylinders as it sits on its all-time high. It has soared in the last five consecutive weeks, the longest streak since April 2023.
Comparing Merck & Co With Industry Competitors In Pharmaceuticals Industry
In today's rapidly changing and highly competitive business world, it is imperative for investors and industry observers to carefully assess companies before making investment choices. In this article...
We like to think UK health services aren’t influenced by big money. That’s just not true | Margaret McCartney
There must be transparency over funding to medics from the pharmaceutical industry – and that’s only the start Shouldn’t we be able to trust doctors to give us independent advice? Earlier this year, t...
AstraZeneca Threatens To Move Vaccine Production Amid Reduced State Support
AstraZeneca Plc (NASDAQ: AZN) has reportedly warned that it might relocate its vaccine manufacturing site from Merseyside, U.K., to Philadelphia amid stalled negotiations with the U.K.’s Labour gover...
AstraZeneca refutes report of relocating U.K. vaccine production to U.S.
AstraZeneca refutes report of relocating U.K. vaccine production to U.S.
AstraZeneca warns of shifting UK vaccine production to US, FT reports
Manufacturing could take place in India, where the company has produced vaccines in the past
AstraZeneca warns of moving UK vaccine production to US, FT reports
AstraZeneca has warned it could relocate its vaccine manufacturing site from the UK to the U.S. amid a deadlock in negotiations with the Labour government over plans to cut state aid promised to the p...
AstraZeneca Is a Cancer Leader. Obesity Could Be a Bonus.
The Anglo-Swedish drugmaker remains one of the best bets in Big Pharma, and potential success in obesity isn’t priced in to the stock.
AstraZeneca Is a Cancer Leader. Obesity Could Be a Bonus.
This column is part of the eighth annual Heard on the Street stock picking contest.
Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings
In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comp...
ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer
Daiichi Sankyo and AstraZeneca's ENHERTU has now been granted eight Breakthrough Therapy Designations with latest based on DESTINY-Breast06 phase 3 trial results Eleventh Breakthrough Therapy Designat...
ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer.
How AstraZeneca built its £200bn medicine cabinet
Under the leadership of Sir Pascal Soriot, the pharmaceuticals giant is one of Britain's greatest success stories.
Pfizer, BioNTech's COVID-19/Flu Combo Vaccine Fails To Meet Key Goal In Late-Stage Study
On Friday, Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) released topline results from the Phase 3 trial of the combined mRNA vaccine candidate against influenza and COVID-19 in healthy ind...
AstraZeneca Imfinzi label expanded in U.S. for lung cancer
AstraZeneca's (AZN) receives FDA approval to use its anti-PD-L1 immunotherapy for another indication in lung cancer, Read more here.
AstraZeneca Imfinzi label expanded in U.S. for lung cancer
AstraZeneca's (AZN) receives FDA approval to use its anti-PD-L1 immunotherapy for another indication in lung cancer, Read more here.
US FDA approves AstraZeneca's non-small cell lung cancer treatment
The drug is already approved in the U.S. for patients with a late-stage form of the disease
US FDA approves AstraZeneca's Imfinzi for lung cancer treatment
The U.S. Food and Drug Administration approved AstraZeneca's blockbuster cancer drug, Imfinzi, for the treatment of patients with a type of non-small cell lung cancer on Thursday.
AstraZeneca Imfinzi Combo Gets EU Nod for Uterine Cancer
AstraZeneca (NASDAQ: AZN) announced that the combination therapy of its PD-L1 inhibitor, Imfinzi (durvalumab), and PARP inhibitor, Lynparza (olaparib), has been approved in the EU to treat certain pa...
Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations
The Biden administration announced that Medicare’s newly negotiated prescription drug prices are expected to save the U.S. government $6 billion in the first year alone . The lower prices, a result of...
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
Diabetes treatments from Merck, Novo Nordisk and AstraZeneca will face the steepest cuts under the IRA, a list showed Thursday.
AstraZeneca's Imfinzi gets FDA priority review for type of lung cancer
AstraZeneca said on Thursday the U.S. Food and Drug Administration (FDA) has granted its cancer drug Imfinzi a priority review for patients with limited-stage small cell lung cancer in the United Stat...
Reeves should nail down UK AstraZeneca deal. A collapse would be embarrassing
Chancellor hopes to cut state aid for Speke vaccine plant to £40m. But pro-growth Treasury must not let project slip overseas • Blow to AstraZeneca vaccine project as Reeves plans funding cuts The int...